Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Outcome of Elderly Patients with DLBCL Failing R-CHOP: The Role of Rituximab and High Dose Therapy in Second Line Treatment. A Retrospective Analysis From the RICOVER 60 Trial.

Bertram Glass, MD, PhD, Andrea Borgerding, Marita Ziepert, Maike Nickelsen, Markus Loeffler, Prof., Michael Pfreundschuh, Lorenz H. Truemper, MD, Norbert Schmitz

Blood (2009) 114 (22): 3714.

https://doi.org/10.1182/blood.V114.22.3714.3714

Published: 2009

Journal Articles

Aggressive Chemotherapy (CHOEP-14) and Rituximab or High-Dose Therapy (MegaCHOEP) and Rituximab for Young, High-Risk Patients with Aggressive B-Cell Lymphoma: Results of the MegaCHOEP Trial of the German High — Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Norbert Schmitz, Maike Nickelsen, Marita Ziepert, Matthias Haenel, Peter Borchmann, PD, Dr., Andreas Viardot, Christina Nickenig, Martin Bentz, MD, Christian Peschel, MD, Lorenz Trümper, Markus Loeffler, Michael Pfreundschuh, Bertram Glass, MD, PhD

Blood (2009) 114 (22): 404.

https://doi.org/10.1182/blood.V114.22.404.404

Published: 2009

Journal Articles

Allogeneic Stem Cell Transplantation with Intermediate Conditioning Is Effective in High Risk Relapse and Progressive Disease of Aggressive Non-Hodgkin-Lymphoma.

Bertram Glass, MD, PhD, Justin Hasenkamp, MD, Anke Goerlitz, Peter Dreger, Joerg Schubert, MD, Gerald Wulf, MD, Maike Nickelsen, Lorenz H. Truemper, MD, Norbert Schmitz

Blood (2009) 114 (22): 3379.

https://doi.org/10.1182/blood.V114.22.3379.3379

Published: 2009

Journal Articles

Prognostic Factors for Outcome of Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Final Results from a Prospective Multicenter Trial (GCLLSG CLL3X study)

Peter Dreger, MD, Stephan Stilgenbauer, MD, PhD, Sebastian Boettcher, MD, Matthias Ritgen, Sascha Dietrich, Donald Bunjes, MD, Dietrich Wilhelm Beelen, MD, Sandra Cohen, MD, FRCP(C), Ute Hegenbart, Joerg Schubert, MD, Michael Stadler, MD, Bertram Glass, MD, PhD, Andreas Burchert, MD, Lutz Uharek, Michael Hallek, Michael Kneba, MD, PhD, Norbert Schmitz, MD, Hartmut Döhner

Blood (2008) 112 (11): 565.

https://doi.org/10.1182/blood.V112.11.565.565

Published: 2008

Journal Articles

Allogeneic Stem Cell Transplantation Results in a Low Relapse Rate in Patients with Peripheral T-Cell Lymphoma.

Maike Nickelsen, MD, Carmen Canals, Sr., Charalampia Kyriakou, MD, PhD, Norbert Schmitz, MD, PhD, Agnes Buzyn, MD, Monika Engelhardt, MD, PhD, Bertram Glass, MD, PhD, Eulogio Conde, MD, Armando Lopez-Guillermo, MD, Gerard Socie, MD, PhD, Anna Sureda, MD, PhD

Blood (2008) 112 (11): 974.

https://doi.org/10.1182/blood.V112.11.974.974

Published: 2008

Journal Articles

Patients with Mature T-Cell Lymphoma Show High Relapse Rates after High Dose Therapy and Autologous Stem Cell Transplantation

Maike Nickelsen, MD, Carmen Canals, Sr., MD, Norbert Schmitz, MD, PhD, Charalampia Kyriakou, MD, PhD, Monika Engelhardt, MD, PhD, Thomas Relander, MD, Werner Linkesch, MD, PhD, Vladimir Koza, MD, Giovanna Meloni, MD, Armando Lopez-Guillermo, MD, Karel Indrac, MD, Dolores Caballero, MD, Hannes Wandt, MD, PhD, Niklas Theorin, MD, Bertram Glass, MD, PhD, Anna Sureda, MD, PhD

Blood (2008) 112 (11): 774.

https://doi.org/10.1182/blood.V112.11.774.774

Published: 2008

Journal Articles

Prevention of Veno-Occlusive Disease in Hematopoietic Stem Cell Transplantation Due to Defibrotide Prophylaxis.

Justin Hasenkamp, MD, Imme Conradi, MD, Gerald Wulf, MD, PhD, Wolfram Jung, MD, Lorenz Truemper, MD, PhD, Bertram Glass, MD, PhD

Blood (2004) 104 (11): 1139.

https://doi.org/10.1182/blood.V104.11.1139.1139

Published: 2004

Journal Articles

Early Dose Intensity Is Critical in Patients with Aggressive Lymphoma: A Randomized study Comparing Identical Doses of Cyclophosphamide, Adriamycin, Vincristine, Etoposide, and Prednisolone given as 4 or 6 cycles followed by Repetitive Transplantation of Stem Cells (Mega-CHOEP).

Bertram Glass, MD, PhD, Marita Kloess, Marcel Reiser, MD, Wolfgang E. Berdel, MD, PhD, Anthony D. Ho, MD, PhD, Lorenz Truemper, MD, PhD, Marcus Loeffler, MD, PhD, Michael Pfreundschuh, MD, PhD, Norbert Schmitz, MD, PhD

Blood (2004) 104 (11): 9.

https://doi.org/10.1182/blood.V104.11.9.9

Published: 2004

Journal Articles

Repetitive High-Dose Therapy with Dose Escalated CHOP + Etoposide Followed by Autologous Stem Cell Transplantation (Mega-CHOEP) in Younger Patients with Primary Diagnosis of Aggressive NHL and Elevated LDH at Diagnosis: Final Analysis.

Norbert Schmitz, MD, PhD, Marita Kloess, Andreas Engert, MD, PhD, Wolfgang E. Berdel, MD, PhD, Bernd Metzner, MD, Lorenz Truemper, MD, PhD, Marcus Loeffler, MD, PhD, Michael Pfreundschuh, MD, PhD, Bertram Glass, MD, PhD

Blood (2004) 104 (11): 610.

https://doi.org/10.1182/blood.V104.11.610.610

Published: 2004

NARROW

Outcome of Elderly Patients with DLBCL Failing R-CHOP: The Role of Rituximab and High Dose Therapy in Second Line Treatment. A Retrospective Analysis From the RICOVER 60 Trial.

Aggressive Chemotherapy (CHOEP-14) and Rituximab or High-Dose Therapy (MegaCHOEP) and Rituximab for Young, High-Risk Patients with Aggressive B-Cell Lymphoma: Results of the MegaCHOEP Trial of the German High — Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Allogeneic Stem Cell Transplantation with Intermediate Conditioning Is Effective in High Risk Relapse and Progressive Disease of Aggressive Non-Hodgkin-Lymphoma.

Prognostic Factors for Outcome of Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Final Results from a Prospective Multicenter Trial (GCLLSG CLL3X study)

Allogeneic Stem Cell Transplantation Results in a Low Relapse Rate in Patients with Peripheral T-Cell Lymphoma.

Patients with Mature T-Cell Lymphoma Show High Relapse Rates after High Dose Therapy and Autologous Stem Cell Transplantation

Prevention of Veno-Occlusive Disease in Hematopoietic Stem Cell Transplantation Due to Defibrotide Prophylaxis.

Early Dose Intensity Is Critical in Patients with Aggressive Lymphoma: A Randomized study Comparing Identical Doses of Cyclophosphamide, Adriamycin, Vincristine, Etoposide, and Prednisolone given as 4 or 6 cycles followed by Repetitive Transplantation of Stem Cells (Mega-CHOEP).

Repetitive High-Dose Therapy with Dose Escalated CHOP + Etoposide Followed by Autologous Stem Cell Transplantation (Mega-CHOEP) in Younger Patients with Primary Diagnosis of Aggressive NHL and Elevated LDH at Diagnosis: Final Analysis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only